Drug intelligence / Profile preview

lactobacillus salivarius PS7

Development stage: Unknown
Lead developer: ProbiSearch
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus salivarius PS7 is a probiotic bacterial strain investigated for its potential to prevent recurrent acute otitis media (AOM) in children. As a live biotherapeutic, it is intended to colonize the upper respiratory tract and nasopharynx, where it may inhibit the growth and colonization of common otopathogens through competitive exclusion, production of antimicrobial compounds, and modulation of the local immune response. The strain was evaluated in the PROMAR clinical trial, a randomized, double-blind, placebo-controlled study designed to assess its efficacy in reducing the frequency of AOM episodes over a six-month administration period.

Other names: Ligilactobacillus salivarius PS7L. salivarius PS7

Beyond the preview

Go deeper on lactobacillus salivarius PS7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus salivarius PS7.

Explore the full profile